FlareOn Biotech
Description
We will be there for the pitching session, but we won't participate in one-to-one meetings.
FlareOn Biotech provides a new rapid tool for assessing tumor margins in the case of Head and Neck Squamous-Cell Carcinoma (HNSCC) right in the operating room. Our patented sensor flares up in response to active proteases within excised tumorous tissue, aiding surgeons in making critical decisions at the point-of-need to ensure complete cancer removal.
Precise surgical removal of a tumor is crucial for a successful therapy, as tumors must be removed with sufficient safety margins (in-sano resection), while keeping the removal of healthy tissue to a minimum in order to avoid significant impairments for the patient. The current gold standard is a resource-intensive and time-consuming histopathological examinations. The waiting time during these examinations leads to inactivity of the surgeons and prolongs the anesthesia time for the patients. In addition, a second procedure may still be necessary due to inadequate or incorrect diagnostics.
By shifting the detection process to the operating room and enabling immediate visualization, we significantly decrease the detection time, allowing multiple tests to be conducted during surgery. Our patented sensors provide access to a more detailed mapping of the tumor extension, facilitating a gentler in-sano resection and enhancing diagnostic accuracy. This advancement could lead to shorter operation times, improved recurrence rates, reduced morbidity, potentially lower mortality, and cost savings.
